June 2020

Dear Friend of TAG:

In these unprecedented times, I’m prouder than ever to share with you highlights from TAG’s life-saving work. As you’ll see in this 2019 Annual Report, TAG achieved major victories in the struggle to end HIV, hepatitis C virus (HCV), and tuberculosis (TB) in the U.S. and around the world.

Despite an unfavorable political climate, TAG secured historic federal funding increases for research across all three disease areas, for programs to address domestic HIV and opioid-related infectious diseases including HCV, and for global TB programs. TAG’s hard-hitting activism convinced the Food and Drug Administration (FDA) to hold Gilead accountable for not studying their new PrEP option in women. New York State and City, catalyzed by TAG and partners, are closer than ever to reaching ending the HIV epidemic targets. TAG launched the first-ever HCV diagnostics literacy program for community advocates. TAG’s TB project’s years of advocacy for research funding led to a landmark $900 million in annual global TB research investments.

Your support makes us stronger. As we confront the challenges of 2020 head on—from accelerating the end of HIV, HCV, and TB to working tirelessly for a better response to COVID-19—we ask that you continue supporting our work, and thank you on behalf of everyone here at TAG.

Be safe, stay well, and thank you!

Yours in the struggle,

Barbara Hughes
President, Board of Directors
TAG’s 2019 Research in Action Awards took place on November 14, 2019, at Town Stages in New York City. Our distinguished honorees this year were: **David France**, Oscar-nominated filmmaker, *New York Times* best-selling author, award-winning investigative journalist, and director of *How to Survive a Plague* and *The Death and Life of Marsha P. Johnson*; **Matthew Lopez**, Olivier Award-winning playwright/screenwriter and author of the play, *The Inheritance*; **Amanda Lugg**, long-time activist and Director of Advocacy and LGBT Programming at African Services Committee; and **Dr. John ‘Jack’ Steever**, Assistant Professor of Pediatrics, The Mount Sinai Adolescent Health Center, Mount Sinai Medical Center, specializing in HIV prevention and treatment in young LGBTQ people. **Tom Kirdahy**, Broadway producer, attorney, and human rights advocate was our honorary event chair. All photos by Alan Barnett Photography.
HIV PROJECT

In 2019, TAG advanced our life-saving work of ensuring progress on research toward improved HIV prevention and a cure, and accelerating the end of HIV as an epidemic. At the start of the year, the President announced the Ending the HIV Epidemic initiative to first stop new transmissions in 57 jurisdictions, and eventually bring the whole nation below epidemic levels by 2030. This initiative presents a huge opportunity, while highlighting several crucial gaps. TAG supported the ACT NOW: END AIDS Coalition, of which we are a co-founder, in delineating core community principles needed to actually end the epidemic for everyone in the U.S. These core principles are especially important for vulnerable populations who are threatened by other administration policies. To ensure that jurisdictional plans to end the epidemic reflect community priorities, we took the lead in launching a new ACT NOW: END AIDS Coalition initiative to support community organizations representing some of the hardest hit communities to participate in their local Ending the HIV Epidemic planning. In New York, we continued to advance the end of the HIV epidemic, celebrating progress—including a 28% drop in new diagnoses in New York State between 2014 and 2018—while also calling attention to key unmet needs, including accessible prevention and testing for young people of color and transgender communities.

We fought back against unfair pricing and access policies that threaten the ability to end HIV. As you’ll read more about in our Policy update, we submitted testimony to Congress on the need to reduce the high price of pre-exposure prophylaxis (PrEP). We pushed back against the U.S. government’s plan to pay Gilead millions of dollars to distribute its own product as part of the Ready, Set, PrEP program, and supported a rejection of Gilead’s claims over PrEP patents resulting from government-funded research. TAG led a group of eight HIV research and advocacy groups in filing a friend-of-the-court brief in support of the plaintiffs in Staley v. Gilead, who filed suit against four drug companies for price-fixing and keeping generic drugs off the market.

TAG pushed the U.S. Food and Drug Administration (FDA) to hold a public hearing on Gilead’s application for approval of their new PrEP option to review lack of inclusion of key populations in research, lack of transparency, and the need for a clear generic pathway. Our testimony and that of partners led to the FDA requiring further research in individuals at risk for vaginal exposure to HIV, including cisgender women and transgender men.

Furthering community-inclusive research, TAG launched a survey on community perspectives on the future of HIV prevention trials. We led an analysis of HIV cure-related clinical trials in 2019, publishing findings that highlight important issues, such as the continuing underrepresentation of women in cure research. TAG’s Cure Research Media Monitor tracked progress on HIV cure research and debunked myths, and our first-ever Pipeline Report on sexually transmitted infections analyzed prospects and needs for improving prevention and treatment for gonorrhea, chlamydia, and syphilis.

TAG’s 2019 HIV Publications

- Gene Editing in HIV Research
- A Landscape Analysis of HIV Cure-Related Clinical Trials in 2018
- Pipeline for Gonorrhea, Chlamydia, and Syphilis
- Antiretroviral Therapy Pipeline
- HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline
- Research Toward a Cure and Immune-Based Therapies Pipeline
- From Engagement to Leadership: Placing Community Priorities at the Heart of HIV Prevention Research (TAGline May 2019)
- Scientific Complexity and Ethical Uncertainties: The Importance of Community Engagement in HIV Cure Research (TAGline May 2019)
- Dispatches from the War on Science (TAGline November 2019)
TAG’s policy team achieved historic wins in 2019 towards ending HIV, tuberculosis (TB), and hepatitis C virus (HCV). In the final budget passed by Congress and signed by the President in December 2019, TAG and our partners secured FY20 federal funding increases for global TB programs and research ($8 million increase), HIV research ($25 million increase), opioid-related infectious disease lines ($5 million increase), HCV vaccine research ($8 million), and new initiatives under the administration’s Ending the HIV Epidemic goals ($140 million increase).

We influenced policy and legislation to improve access to medicines. Our input to Speaker Pelosi’s office strengthened and broadened drug pricing reforms in the Elijah E. Cummings Lower Drug Costs Now Act, which the House passed. TAG was specifically called upon by the House Committee on Oversight and Reform to submit testimony for a Congressional hearing investigating Gilead’s high pricing of Truvada for PrEP. Preparing for the 2020 election cycle within parameters permissible for 501(c)3 organizations, TAG and the ACT NOW: END AIDS Coalition engaged with 2020 presidential candidate campaign offices about their platforms and policy plans to end the HIV epidemic.

To advance efforts to end TB, TAG co-organized a Congressional briefing and a series of advocacy trainings to build capacity for legislative campaigns. These collaborative efforts resulted in new bipartisan Congressional endorsements for the Comprehensive TB Elimination Act (which includes provisions for research as well as domestic TB programs), and the introduction of the End TB Now Act (which supports global TB programming and research). Under a new partnership with the National TB Controllers Association, TAG continued to support a cutting-edge TB response in New York, and launched community engagement initiatives in Indiana, Los Angeles County, and Louisiana to support those and other jurisdictions’ efforts to end TB. Policy staff advanced the concept of “fair share” funding targets for TB research, building awareness in the White House Office of Management and Budget, the State Department, and the Department of Health and Human Services, and cultivating buy-in from key federal agencies involved in TB research to hit the U.S. target.

Back in New York, TAG advanced the end of HCV in the state by working with the Surveillance, Data, and Metrics working group of the New York State HCV Elimination Task Force to generate recommendations for the governor, and serving on the Elimination Metrics Advisory Committee to guide the development and monitoring of HCV elimination metrics and progress. In parallel, we initiated a community engagement and advocacy initiative toward viral hepatitis elimination in New York City, coordinating a series of borough events. TAG helped build a citywide coalition in response to deep cuts under Article 6 State matching funds to New York City health programs. This emerging coalition successfully restored $65 million through reallocation of New York City general funds.

We also welcomed the newest junior member of our policy team, Saurav Madoori, baby of proud parents Suraj Madoori (TAG’s Director of U.S. & Global Health Policy) and Shivani Thaker.

TAG’s 2019 Policy Publications

- Closing the Gap in Tuberculosis Research and Development Funding Briefs (for Legislative & Executive Agencies)
- Regime Change in America: Tracking TAG’s Work Across Eight National Election Cycles (TAGline November 2019)
- This Is Not a Drill: Science, Solidarity and the 2020 Elections (TAGline November 2019)
TAG’s groundbreaking HCV community engagement and advocacy initiatives in 2019 achieved notable global policy wins. Our actions helped ensure that outcome documents from the United Nations High-Level Meeting on Universal Health Coverage included addressing viral hepatitis. TAG provided vital feedback to raise the importance of hepatitis C activities and to promote harm reduction in the U.S. President’s Emergency Plan For AIDS Relief (PEPFAR) guidance to countries. This feedback resulted in tripling the number of mentions for viral hepatitis in the final PEPFAR guidance released in 2020, which could provide opportunities to integrate hepatitis in country programs.

In partnership with the Foundation for Innovative New Diagnostics (FIND), our HCV Project launched an in-depth diagnostics literacy program for 75 advocates in the countries of Georgia and Malaysia—the first, to our knowledge. Partnering with FIND, the Georgian Harm Reduction Network, and the Georgian Community Advisory Board, TAG provided technical capacity building among community leaders and harm reductionists. Monitoring policy changes continues through a newly formed, community-led steering committee and stronger relationships with the Georgian Ministry of Health. Advocacy workshops with the Positive Malaysian Treatment Access and Advocacy Group, medical providers, and grassroots leaders from drug user, LGBTQ+, and sex worker activist communities, helped make community engagement and decentralized testing integral components in Malaysia’s elimination strategy.

Furthering our technical support for advocates around the world, TAG disseminated critical information and capacity building materials. We expanded our crowdsourced data platform, mapCrowd, to include country-specific information on the latest generic hepatitis C medications and diagnostics. We partnered with Harm Reduction International to integrate data on harm reduction coverage, treatment restrictions, and inclusion of people who use drugs in national strategies. Our collaboration enabled analysis of new data from high-burden countries, including Iran, Nigeria, the Philippines, and Uzbekistan. TAG, the global hepCoalition network (of which we are a co-founder), and partners launched hard-hitting campaigns and fact sheets in multiple languages to assist communities and inform policymakers on progress made towards HCV elimination. The community checklist, Who Counts in Our National Hepatitis Plans?, the Comprehensive HCV Package of Services for People Who Use and Inject Drugs infographic, and Have A Heart, Save My Liver! diagnostics brief have been used by partners to inform community trainings and high-level policy meetings in Georgia, India, Malaysia, Lao People’s Democratic Republic, South Africa, and Tanzania.

TAG spearheaded another campaign, challenging human rights abuses and calling for the release of three detained HIV/HCV lawyers and activists in Changsha, China. This campaign raised awareness among over 15,000 people on social media. TAG campaigned to increase programming and funding for people with HIV/HCV coinfection through the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and continues to advocate for expanded access to generic hepatitis C medications by AbbVie, Gilead, and licensed generic manufacturers.

TAG’s 2019 HCV Publications

- New HCV Fact Sheets for sofosbuvir/daclatasvir and Mavyret (glecaprevir/pibrentasvir)
- Activist Guide to Hepatitis C Virus Diagnostics and training curriculum slide deck
- HCV Diagnostics Pipeline
- HCV Treatment Pipeline
- Love Trumps Hate: Building People Power and Reshaping Political Struggles Toward Harm Reduction, Humanity, and Hope (TAGline November 2019)
TAG’s TB project achieved several victories for TB research and access in 2019. Our decades of TB research funding advocacy have been bearing fruit—our signature report showed that global funding for TB research and development reached a new all-time high in 2018 of over $900 million. The World Health Organization (WHO) incorporated TAG-developed targets for country funding into their Global Strategy for TB Research and Development, and the U.S. government announced meeting its TAG-set target.

TAG’s research advocacy, community engagement efforts, and participation in trial design also contributed to the launch of important studies and the defense of rigorous TB science. A much-anticipated trial from the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group to test a newer drug’s ability to prevent drug-resistant TB started. TAG testified before the FDA regarding pretomanid, a new TB drug, to express concern regarding remaining research questions, and the importance of upholding stringent evidentiary standards for new TB medicines. The TAG-coordinated Community Research Advisors Group (the community advisory board to the Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium) proposed a qualitative study of barriers and facilitators to enrolling adolescents in TB treatment trials; this study also began in 2019.

Our advocacy to ensure that advances of science translate into sound policy similarly achieved success. TAG and partners’ advocacy for WHO guideline changes and participation in guidance development secured life-saving updates. WHO guidance now strongly recommends molecular diagnosis for TB for all, and less toxic, more effective, all-oral regimens for treating drug-resistant TB. As with our HCV project, our TB project successfully influenced PEPFAR’s guidance to countries to promote better TB diagnostics and treatments in global AIDS programs, including TB preventive therapy, pediatric TB interventions, and molecular and rapid TB tests.

To facilitate uptake of evidence-based interventions to end TB, TAG’s TB project advanced several campaigns to increase access to essential TB medicines (bedaquiline, pretomanid, delamanid, and rifapentine) and diagnostics (GeneXpert). These campaigns centered on technologies developed with public and philanthropic funding, but manufactured and sold by companies at unaffordable prices.

Through all this work and more, our TB project engaged and empowered community advocates. Our advocacy workshops on preventive therapy and pediatric TB supported activists in over 15 countries to call for access to preventive therapy and pediatric TB interventions.

We held the first cross-training between TB activists (represented chiefly by the TAG-supported Global TB Community Advisory Board) and access to medicines activists, to foster common understanding, solidarity, and stronger campaigns to improve access to TB commodities.

### TAG’s 2019 TB Publications

- TB LAM Testing Briefs
- An Activist’s Guide to Rifapentine for the Treatment of TB Infection
- 2019 Report on TB Research Funding Trends
- National TB Checklist Update
- TB Activist Toolkits Update
- Pediatric Tuberculosis Diagnosis, Treatment, and Prevention Pipeline
- TB Diagnostics Pipeline
- TB Treatment Pipeline
- TB Vaccines Pipeline
- Sound Off: Three Activists Reflect on Community Victories and Priorities in TB Research (TAGline May 2019)
- The Final Frontier: Breaking Down Barriers to Community Engagement in Diagnostics Research (TAGline May 2019)
### Balance Sheet

<table>
<thead>
<tr>
<th>Assets</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,610,906</td>
<td>$1,534,231</td>
</tr>
<tr>
<td>Unconditional Promises to Give</td>
<td>496,981</td>
<td>1,216,871</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>7,583</td>
<td>1,139</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>37,208</td>
<td>31,594</td>
</tr>
<tr>
<td>Donated artwork</td>
<td>492,739</td>
<td>439,739</td>
</tr>
<tr>
<td>Security deposit</td>
<td>72,463</td>
<td>72,463</td>
</tr>
<tr>
<td>Property and equipment - net</td>
<td>18,580</td>
<td>26,728</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$2,736,460</strong></td>
<td><strong>$3,322,765</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$38,603</td>
<td>$25,396</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>33,362</td>
<td>42,520</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>71,965</strong></td>
<td><strong>67,916</strong></td>
</tr>
<tr>
<td>Net Assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without donor restrictions</td>
<td>1,537,543</td>
<td>1,736,034</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>1,126,952</td>
<td>1,518,815</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>2,664,495</strong></td>
<td><strong>3,254,849</strong></td>
</tr>
</tbody>
</table>

| **Total Liabilities and Net Assets**         | **$2,736,460**            | **$3,322,765**            |

### Statement of Cash Flows

<table>
<thead>
<tr>
<th>Cash Flows from Operating Activities</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase (decrease) in net assets</td>
<td>($590,354)</td>
<td>($701,749)</td>
</tr>
<tr>
<td>Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>9,547</td>
<td>10,873</td>
</tr>
<tr>
<td>(Increase) decrease in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unconditional promises to give</td>
<td>719,890</td>
<td>333,023</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>(6,444)</td>
<td>(1,139)</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(5,614)</td>
<td>(6,210)</td>
</tr>
<tr>
<td>Donated artwork</td>
<td>(53,000)</td>
<td>(25,239)</td>
</tr>
<tr>
<td>Increase (decrease) in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>13,207</td>
<td>(264)</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>(9,158)</td>
<td>(12,549)</td>
</tr>
<tr>
<td><strong>Net Cash Used by Operating Activities</strong></td>
<td><strong>78,074</strong></td>
<td><strong>(403,254)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cash Flows from Investing Activities</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisition of property and equipment</td>
<td>(1,399)</td>
<td>(11,627)</td>
</tr>
<tr>
<td>Proceeds from sales of fixed assets</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net Cash Used by Investing Activities</strong></td>
<td><strong>(1,399)</strong></td>
<td><strong>(11,627)</strong></td>
</tr>
<tr>
<td>Net decrease in cash and cash equivalents</td>
<td>76,675</td>
<td>(414,881)</td>
</tr>
<tr>
<td>Cash and cash equivalents, beginning of year</td>
<td>1,534,231</td>
<td>1,949,112</td>
</tr>
<tr>
<td><strong>Cash and Cash Equivalents, End of Year</strong></td>
<td><strong>$1,610,906</strong></td>
<td><strong>$1,534,231</strong></td>
</tr>
</tbody>
</table>
Statement of Activities

Revenue and Other Support

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$277,143</td>
<td>$1,484,565</td>
<td>$1,761,708</td>
</tr>
<tr>
<td>Fundraising benefit events</td>
<td>287,848</td>
<td>-</td>
<td>287,848</td>
</tr>
<tr>
<td>Less: Direct benefit expenses</td>
<td>(79,422)</td>
<td>-</td>
<td>(79,422)</td>
</tr>
<tr>
<td>Donated artwork, goods and services</td>
<td>174,796</td>
<td>-</td>
<td>174,796</td>
</tr>
<tr>
<td>Art sales, net of cost of goods sold</td>
<td>500</td>
<td>-</td>
<td>500</td>
</tr>
<tr>
<td>Other income</td>
<td>27,143</td>
<td>-</td>
<td>27,143</td>
</tr>
<tr>
<td>Interest income</td>
<td>1,347</td>
<td>-</td>
<td>1,347</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>1,876,428</td>
<td>(1,876,428)</td>
<td>-</td>
</tr>
</tbody>
</table>

Total Revenue and Other Support

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2,566,053</td>
<td>(391,863)</td>
<td>2,174,190</td>
</tr>
</tbody>
</table>

Expenses

Program Services

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Program</td>
<td>590,447</td>
<td>-</td>
<td>590,447</td>
</tr>
<tr>
<td>Hepatitis C Virus Program</td>
<td>307,575</td>
<td>-</td>
<td>307,575</td>
</tr>
<tr>
<td>TB/HIV Program</td>
<td>1,246,647</td>
<td>-</td>
<td>1,246,647</td>
</tr>
</tbody>
</table>

Total Program Services

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2,144,669</td>
<td>-</td>
<td>2,144,669</td>
</tr>
</tbody>
</table>

Supporting Services

<table>
<thead>
<tr>
<th>Supporting Services</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>379,723</td>
<td>-</td>
<td>379,723</td>
</tr>
<tr>
<td>Fundraising</td>
<td>240,152</td>
<td>-</td>
<td>240,152</td>
</tr>
</tbody>
</table>

Total Expenses

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2,764,544</td>
<td>-</td>
<td>2,764,544</td>
</tr>
</tbody>
</table>

Increase (decrease) in net assets

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(198,491)</td>
<td>(391,863)</td>
<td>(590,354)</td>
</tr>
</tbody>
</table>

Net assets, beginning of year

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1,736,034</td>
<td>1,518,815</td>
<td>3,254,849</td>
</tr>
</tbody>
</table>

Net Assets, End of Year

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$1,537,543</td>
<td>$1,126,952</td>
<td>$2,664,495</td>
</tr>
</tbody>
</table>

Summary of 2019 Functional Expenses

- **Program Services**: 77%
- **Management & Administration**: 14%
- **Fundraising**: 9%
$100,000 or more
The Aurum Institute
Bill and Melinda Gates Foundation
ViiV Healthcare

$50,000 to $99,999
Broadway Cares / Equity Fights AIDS
Foundation for Innovative New Diagnostics
Elizabeth Glaser Pediatric AIDS Foundation
Global Drug Facility via Stop TB Partnership
Stop TB Partnership hosted by UNOPS
Joy A. Tomchin
Veterans Affairs Medical Center of Washington, DC

$25,000 to $49,999
The Debs Foundation: Richard A. and Barbara Knowles Debs; Nick Debs
Hauser & Wirth
Fred Hutchinson Cancer Research Center
M•A•C AIDS Fund
Merck & Co.

$20,000 to $4,999
amfAR, The Foundation for AIDS Research
Michael Becker and Tee Scatuorchio
Annie Bennett Glenn Fund in honor of P. Forrest Williams, Jr.
Kevin and Neil Goetz / Screen Engine/ASI
The Great American Songbook Foundation
The Hepatitis C Mentor and Support Group
Marta Heflin Foundation
Bobby McLain and Alberto Blanquel

$5,000 to $9,999
The Calamus Foundation
JPMorgan Chase Foundation in recognition of TAG Board member Richard Lynn
Celeste B. Cooper
David Corkery
The Gendal Family Foundation in honor of Monte Steinman
Richie Jackson and Jordan Roth
Janssen Therapeutics
Jameel Jiwani
Robert W. Lennon and Mark Gilrain
Richard M. Lynn and Joseph Evall
Médecins du Monde
Robert Monteleone
Laura A. Morrison
National Coalition of STD Directors
National TB Controllers Association
Marc Wolinsky and Barry C. Skovgaard

$2,500 to $4,999
1199 SEIU
Abbott Laboratories
Jim Aquino
Jeff D. and Michelle Kleinert Bader
Bob Bronzo
Dr. Joseph Burzynski
Cristopher Canizares
Benson Cohen
John F. Duane and Mary E. Northridge
Marc E. Elovitz in honor of Richard Lynn and Joseph Evall
David France
Suzanne Gay and Bryn M. Gay in memory of Phillips G. Gay, Jr.
Judith and Richard Harrington
Paula Hartstein
Barbara F. Hughes
Noel E.D. Kirnon and Michael D. Paley
Ivy Kwan Arce in memory of Sally C. Cooper, Karina Haslip, and Michael Callen
Dr. J. Michael McCune III and Dr. Karen Kaye Smith-McCune
Eddie Pelto in memory of Daniel A. Volpe, Jr.
Bruce Schackman and Ed Sikov
Jeff Schoenfeld and Matt Holbein
Bill Shea and Frank Selvaggi
The Sigal Family Foundation: David Sigal and New York State Senator Brad Hoylman
Mrinal Vikram and Kevin Finnegan
John Voelcker
Weil, Gotshal & Manges LLP
The Andrew D. Zacks Foundation

$1,000 to $2,499
Amida Care / Doug Wirth
Katherine C. and Thomas M. Ash III in memory of Richard Harrington
AVAC / Mitchell Warren
Jack M. Battaglia
Erica Baum
Michael Bennett in memory of Ty French
Karen Bronzo and Jefferson Rabb
Brooklyn Community Foundation
Steven F. Capone
Lawrence Corey, MD
Jonathan Creighton and Megan Harrington
Michael Cunningham and Ken Corbett
Dick Daday
Ariane Z. Dar / New Ground Fund of Marin Community Foundation
Hon. Thomas K. Duane
Kimberly Elliott in honor of Jane Silver
Ruth Finkelstein and BC Craig
Bruce C. Francis in memory of Rich DeNagel
Fung Chun Bong
Jennifer J. Furin, MD, PhD
Robert Gillard and James Harrington in honor of Monte Steinman
David Gold
David Greenblatt
Mark Harrington
Christina and Kenneth Hecht in memory of Richard Harrington
Hon. James C. Hormel
Housing Works / Charles King
IAVI / Dr. Mark Feinberg, CEO
Tom Kirdahy and the late Terrence McNally in memory of Gary Bonorsate
Emmy Kondo and Danny Rosenthal
Jay Leitz
Michael K. Longacre in memory of Tony Ortiz
Alby P. Maccarone, Jr.
Loring McAlpin
Albert S. Messina and Kenneth L. Jennings in honor of our friend Richard Jacobs
George J. and Miria N. Morrison
Craig Murray in honor of Kevin and Neil Goetz
Otsuka Novel Products GmbH
Marvel S. Platoff Foundation
Kevin Ryan
Andrew C. Schirmeister III in honor of Monte Steinman
Evan Schwartz and Robert Fitterman
H.A. ‘Hal’ Sedgwick in honor of Cassandra Leveille
Kurt R. Soderlund
Rachel B. Tiven and Seth M. Marnin
W. Kirk Wallace and Mark M. Sexton
Thomas P. Wilczak and Steven R. Quinkert
Nadine Witkin

2019 TAG CONTRIBUTORS
$500 to $999
AIDS Action Baltimore
Association of State and Territorial Health Officials
Robert J. and Margot Bazell
Michael Beltran and Timothy Ford
Peter F. Brown and Dr. Margaret Hamburg
Steven J. and Denise Chisholm
Michael Coady
Robert N. Croonquist
Alan Cumming and Grant Shaffer
Paul L. Dietz
Eric Eidelman and Julie A. Mirolla
Stephen A. Foster
Steven M. Frank and Dr. Elizabeth S. Powell
New York State Assembly Member Deborah J. Glick
GMHC / Kelsey Louie
God’s Love We Deliver
Roy M. ‘Trip’ Gulick, MD
Health GAP
Alex Henderson and Oskar Moguel
Robert C. Henry
Drew Hodges and Peter Kukielski
Tim Hosking and Audrey Sokoloff in honor of Rich Lynn for his many and continuing efforts on behalf of TAG
Michael T. Isbell in memory of Spencer Cox
Richard Jeffrey in memory of Richard Harrington
Presston Kennedy in honor of those who have passed and those still fighting
Paul Kennedy
babette Krolik and Sara Rafsky
Burt R. Lazarin
Justin D. Lee and Michael E. Gunther
David C. Levine
Joseph McConnell and Erik Haagensen
Jeff Mendoza and Dr. Chuck Sklar
Sally Morrison in honor of Dr. Lucy Painter
Mount Sinai Institute for Advanced Medicine
John Nesbit and Cristina Corbin
Kim Nichols in honor of Amanda Lugg
Natalie Olstein in honor of Bobby Rosenthal, to honor his mother Suzanne Benzer on her 80th birthday; a gift from her friends
Jason Osher and Richard Schubel
Daniel Ptacek
Robert H. Remien
Walter Rieman in memory of Tom Stoddard
Roche / Robin Thomas
Jamie Saakvitne and Daniel Chow in honor of Dr. John B. Steever
Greig Sargeant
Lyle Saunders in honor of Laura Morrison
Peter A. Schamel
Sarah F. and Roy E. Schutzengel in memory of Harley Fleischmann
Stephan Shaw and Sunita Viswanath
David R. Shaw and Francesca Zaccheo
Andrew Shih
Virginia Shubert and David Sipress
Jane Silver
Peter Staley
Monte Steinman
Marc Szafra
Cathy E. Taub and Lowell C. Freiberg
Keith S. Tobin, MD
Dennis Trufnfo
Paolo Danilo Vicino
Lisa Volling in honor of Jameel Jwani
P. Forrest Williams, Jr.

$250 to $499
Michele Araujo
Joe Baker in honor of Tom Kirdahy, for the Opening of “The Inheritance”
Alvin Baum in memory of Richard Harrington of San Francisco, father of Mark Harrington
Robert Beatty in honor of Monte Steinman
Danielle Benz in honor of Jameel Jwani
Jessica Boyle
Richard Cardillo in memory of Peter F. Diffly, Jr.
Dr. Charles C.J. Carpenter and Mrs. Sally F. Carpenter
Patricia Costello in memory of Jim Konetsky
Scott Dainton
Judith Davis-Fagan
Lynda Dee, Esq.
Peter Morris Dixon
Jim Eigo
Jennifer Eisenstadt in honor of Dr. John Steever
Paula Elbrit in honor of Dr. John B. Steever
Monica Gerber
Leslie Asako Gladjsjo
Ron Goldberg
Joy Harris
Drew Hodges in honor of Tom Kirdahy, for the Opening of “The Inheritance”
Kevin Jennings and Jeff Davis in honor of David France
Jay Johnson and Thomas Cashin
Hooman Kamel in honor of the PrEP4All Collaboration
Jeremy Kawaller
Sung Woon Kil in honor of Bob Bronzo
James Krellenstein
Joseph Lauretano
Charles S. Laven
Susan Leimsider in honor of Erica Lessem
Claire Lennon
Margaret Lennon

Linda Liedtke
Mayo Schreiber
Merle C. McCann MD in memory of John Stuban
Fernando J. Alva Miras
Joseph S. Monteleone
Fraser D. ‘Skip’ Mooney
Dr. Steven S. Muchnick and Eric Milliren
Scott Newman
Ann Northrop
Kathleen O’Leary in honor of Bob Bronzo
Stephanie Oster
Pam Parker
Laura Pinsky in memory of Rich DeNagel
Sheila Reeves
Clifford Richner
Erica Rosengart
 Kimberleigh Smith in honor of Amanda Lugg
Robin Thomas
Oliver R. Tobin
Barbara Toll in honor of Jeff Mendoza
Christian Urrutia
plus donations from an additional 195 generous contributors, including Anonymous gifts

We would also like to thank those who gave generously to TAG as part of campaigns hosted via Act Blue Charities, PayPal Charitable Giving (for Board member Jim Aquino’s participation in the Boston Marathon), and Network for Good (Board member Eddie Pelto’s FaceBook campaign).

TAG was the beneficiary of funds raised as part of the 2019 NYC AIDS Walk, and through participation in the Amazon Smile program.

TAG would like to thank artist Glenn Ligon, Print Positive NY, SpotCo, and Board members Kevin Goetz and Jeff Mendoza for their generous in-kind donation of goods and services, to support fundraising events that benefitted TAG.
About TAG

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

TAG works to ensure that all people with HIV, TB, or HCV receive lifesaving treatment, care, and information.

We’re science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.

TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end HIV, TB, and HCV.

Support TAG

In 2019, TAG made many strides against HIV, HCV, and TB. In 2020, we continue our vital core work to end HIV, HCV, and TB, while applying our expertise to the COVID-19 pandemic. A robust response based on science and driven by community priorities is more crucial than ever.

Make a gift to TAG and help us advocate for the needs of all people affected by HIV, HCV, TB, and COVID-19.

Support TAG today: www.treatmentactiongroup.org/support.

Does your organization have a matching gifts program? Don’t miss your chance to make a gift that keeps on giving. Complete and send us your company’s matching gift form to double your contribution’s impact!

Thank You, Board Members

The Board and Staff of Treatment Action Group thanks Bobby McLain, Jeff Mendoza, and Monte Steinman for their years of dedicated and significant service on TAG’s Board of Directors.

TAG Limited Art Editions

Each year at its Research in Action Awards, TAG presents a new, limited edition work of art. Past artists include Glenn Ligon, Zoe Leonard, Erica Baum, Rosalind Fox Solomon, Joy Episalla, Kate Shepherd, Nan Goldin, Robert Gober, Bill Jacobson, fierce pussy, Donald Moffett, Tony Feher, Carrie Yamaoka, David Armstrong, and Richard Renaldi.

TAG retains an inventory of many of the editions for sale to the public, and all proceeds benefit TAG’s work. If you’re interested in purchasing an edition or learning more about the available editions, detailed information can be found at http://www.treatmentactiongroup.org/limited-art-editions.

Glenn Ligon Black Rage (back cover), 2019

2020 BOARD OF DIRECTORS

PRESIDENT: Barbara Hughes
VICE PRESIDENT: Robert W. Lennon
SECRETARY/TREASURER: Laura Morrison
Jim Aquino
Frank Bua
Dick Dadey
Nick Debs
Joy Episalla
Kevin Goetz
Roy Gulick, M.D.
Jameel Jiwani
Richard Lynn, Ph.D., M.P.H.
Robert Monteleone
Eddie Pelto
David Sigal
Mrinal Vikram

2020 STAFF

EXECUTIVE DIRECTOR: Mark Harrington
DEPUTY EXECUTIVE DIRECTOR: Erica Lessem
TB PROJECT OFFICER: David Branigan
TB PROJECT CO-DIRECTOR: Mike Frick
STATE AND LOCAL POLICY DIRECTOR: Annette Gaudino
HCV PROJECT DIRECTOR: Bryn Gay
FINANCE MANAGER: Christopher George
DIRECTOR OF FINANCE AND OPERATIONS: Sabrina Guerrero-Morris
BASIC SCIENCE, VACCINES, AND CURE PROJECT DIRECTOR: Richard Jefferys
HIV PROJECT DIRECTOR: Jeremiah Johnson
GRANT OFFICER: Jason Kirk
GOVERNMENT RELATIONS AND POLICY OFFICER: Elizabeth Lovinger
U.S. AND GLOBAL HEALTH POLICY DIRECTOR: Suraj Madoori
ADMINISTRATOR: Joseph McConnell
TB PROJECT CO-DIRECTOR: Lindsay McKenna
COMMUNICATIONS MANAGER: Dorrit Walsh